Geode Capital Management
STLN

Geode Capital Management’s Starling Oncology STLN Stock Holding History

Geode Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
1,899,998
+142,151
+8% +$597K ﹤0.01% 2524
2026
Q1 		$5.4M Buy
1,757,847
+187,393
+12% +$575K ﹤0.01% 2700
2025
Q4 		$5.59M Buy
1,570,454
+168,548
+12% +$625K ﹤0.01% 2709
2025
Q3 		$4.89M Buy
1,401,906
+122,463
+10% +$420K ﹤0.01% 2791
2025
Q2 		$2.62M Buy
1,279,443
+893,696
+232% +$2.23M ﹤0.01% 3049
2025
Q1 		$440K Buy
385,747
+38,400
+11% +$29.7K ﹤0.01% 3589
2024
Q4 		$107K Sell
347,347
-32,634
-9% -$8.46K ﹤0.01% 4080
2024
Q3 		$124K Buy
379,981
+19,717
+5% +$8.17K ﹤0.01% 4042
2024
Q2 		$166K Buy
360,264
+6,166
+2% +$5.26K ﹤0.01% 3982
2024
Q1 		$560K Buy
354,098
+14,331
+4% +$27.2K ﹤0.01% 3569
2023
Q4 		$693K Buy
339,767
+34,266
+11% +$59.4K ﹤0.01% 3488
2023
Q3 		$428K Buy
305,501
+45,082
+17% +$46.7K ﹤0.01% 3659
2023
Q2 		$143K Sell
260,419
-271,648
-51% -$144K ﹤0.01% 4195
2023
Q1 		$361K Buy
532,067
+2,447
+0.5% +$3.12K ﹤0.01% 3780
2022
Q4 		$873K Buy
529,620
+8,322
+2% +$23.4K ﹤0.01% 3409
2022
Q3 		$2.41M Buy
521,298
+275,907
+112% +$1.62M ﹤0.01% 3024
2022
Q2 		$1.24M Buy
245,391
+164,989
+205% +$1.2M ﹤0.01% 3320
2022
Q1 		$573K Buy
80,402
+69,255
+621% +$467K ﹤0.01% 3867
2021
Q4 		$108K Buy
+11,147
New +$99.1K ﹤0.01% 4704
2021
Q1 		– Sell
-10,327
Closed -$113K – 4466
2020
Q4 		$113K Sell
10,327
-39,673
-79% -$408K ﹤0.01% 4035
2020
Q3 		$491K Buy
+50,000
New +$519K ﹤0.01% 3436

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Geode Capital Management's STLN Position: Q2 2026 in Review

Geode Capital Management increased its Starling Oncology (STLN) stake by 8.1% in Q2 2026, buying an estimated $597K and bringing the position to 1,899,998 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

Geode Capital Management first reported a position in STLN in Q3 2020 and has held it in 21 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Geode Capital Management held 1,899,998 shares of Starling Oncology worth $10.3M as of Q2 2026.
  • Geode Capital Management bought 142,151 Starling Oncology shares in Q2 2026, an estimated $597K.
  • Starling Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2524 holding.
  • Geode Capital Management first reported a position in Starling Oncology in Q3 2020 and has held it in 21 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.